Consensus estimates project a $0.27 EPS loss and $0.35M revenue for EVGN in Q1 2026, both reflecting year-over-year declines.
Evogene (EVGN) will report Q1 2026 earnings before the market opens on May 20. Analysts expect a loss of $0.27 per share, an improvement from the prior year, and revenue of $0.35 million, down sharply year-over-year.
Over the past two years, EVGN has beaten EPS estimates 63% of the time but met revenue estimates only half the time. The company has faced challenges in revenue growth despite occasional earnings surprises.
No immediate market reaction details were provided ahead of the release.